Henogen S.A. acquires 4C Biotech S.A.

02-Jul-2003
Henogen, located at Charleroi in Belgium, has recently closed the acquisition of 4C Biotech, Seneffe, a Contract Manufacturing Organization dedicated to the development of mammalian cell culture processes for the production of biotherapeutics. This acquisition extends the existing services portfolio of Henogen « from gene to GMP clinical batch production « to the large scale production of monoclonal antibodies and recombinant proteins. The new 60 people strong company will operate on two GMP sites, with more than 10 BL2/BL3 culture and purification suites equipped with the latest bioreactors up to 300L capacity . · The site of Charleroi will be dedicated to the bacteria, yeast, baculovirus and viral vectors productions. · The site of Seneffe will be dedicated to the large scale production of monoclonal antibodies and recombinant proteins thanks to its historical know-how regarding the perfused culture of mammalian cells . Henogen now offers to the biopharmaceutical community a very complete services portfolio which starts from the molecular biology and the choice of the best Expression system up to the sterile filling and the release of phase I/II clinical grade material. Quite unique in Europe, such an integrated service targets a wide range of customers whether large pharmaceutical companies, innovative drug discovery biotech SME's or health related public institutions.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous